AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02930811
Drug: Sildenafil 100 mg oral morning dose
RxNorm normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months
Trial: NCT05307081
Drug: Artificial Tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artificial Tears are an FDA approved intervention
Trial: NCT06073769
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance therapy according to the approved label
Trial: NCT06488625
Drug: Low-Dose CICR-NAM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 g/d CICR-NAM (blinded)
Trial: NCT06488625
Drug: Open-Label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d CICR-NAM (open label)
Trial: NCT05961397
Drug: baxdrostat
RxNorm normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of baxdrostat 10 mg
Trial: NCT05135182
Drug: Furazolidone
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone-tetracycline-containing quadruple regimens
Trial: NCT05135182
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazole-tetracycline-containing quadruple regimens
Trial: NCT04773678
Drug: CBP-201
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP-201 subcutaneous (SC) injection.
Trial: NCT04928703
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine IV administration
Trial: NCT04992572
Drug: Propofol Injection
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg Propofol administered by injection
Trial: NCT04992572
Drug: Lidocaine Hydrochloride, Injectable
RxNorm normalized name: Lidocaine Hydrochloride, Injectable
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licocaine administered locally via injection.
Trial: NCT05254925
Drug: Sunscreen oil with 6% Bemotrizinol
DrugBank: Bemotrizinol (DB11206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
Trial: NCT05254925
Drug: Dispersion of 6% BEMT in petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
Trial: NCT05241262
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
Trial: NCT06112665
Drug: Tofacitinib 5 MG
RxNorm normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive Tofacitinib and Naproxene
Trial: NCT05952349
Drug: OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
Trial: NCT05952349
Drug: Metformin (1000 mg Twice a day)
RxNorm normalized name: metformin 1000 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 44 Patients with PCOS receiving Metformin 1000mg (BD)
Trial: NCT06345716
Drug: paracétamol tramadol
RxNorm normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
Trial: NCT06345716
Drug: Paracétamol cafeine
RxNorm normalized name: Caféine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
Trial: NCT03301558
Drug: Low dose sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1500 mg sodium bicarbonate
Trial: NCT03301558
Drug: High dose sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3000 mg sodium bicarbonate
Trial: NCT03941496
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay
Trial: NCT04211649
Drug: 3 days of antibiotherapy
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
Trial: NCT06532643
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
Trial: NCT05789745
Drug: Recombinant human plasma gelsolin
RxNorm normalized name: Recombinant human plasma gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
Trial: NCT06676644
Drug: adjuvanted
RxNorm normalized name: PIKA-adjuvanted rabies vaccine
DrugBank: Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine (DB16757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
Trial: NCT05520658
Drug: combined digoxin and furosemide
RxNorm normalized name: furosemide and potassium
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one session every 2 weeks for maximum 6 sessions
Trial: NCT06468098
Drug: IBI363 + chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, patients will receive IBI363 and chemotherapy
Trial: NCT06459063
Drug: Allocetra - Safety run-in phase
RxNorm normalized name: allantoin
DrugBank: Allocetra (DB16424)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
Trial: NCT06459063
Drug: Allocetra - Randomization phase
RxNorm normalized name: jojoba oil, randomized
DrugBank: Allocetra (DB16424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
Trial: NCT04976309
Drug: Lu AG09222
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT04709250
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine
Trial: NCT05740488
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240mg, po, qd
Trial: NCT05740488
Drug: 89Sr
RxNorm normalized name: strontium (89Sr) chloride
DrugBank: Strontium chloride (DB13987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100\~150MBq(based on weight), iv, q90d
Trial: NCT06223880
Drug: AXS-05
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period
Trial: NCT05740488
Drug: Luteinizing Hormone-Releasing Hormone Analog
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sc, 3.6mg, q30d or 10.8mg, q90d
Trial: NCT06223880
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 26 weeks in double-blind period
Trial: NCT05531786
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
Trial: NCT05022693
Drug: BIO89-100
RxNorm normalized name: Bio89-100 (long-acting glycopegylated fibroblast growth factor 21 (fgf21) analogue)
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injections
Trial: NCT03278314
Drug: tezacaftor/ivacaftor
RxNorm normalized name: ELEXACAFTOR/TEZACAFTOR/IVACAFTOR 100-50-75MG/75MG PKT,14
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: orally administered TEZ/IVA combination therapy
Trial: NCT05639777
Drug: Dexmedetomidine group
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: That will receive intranasal dexmedetomidine (1.5mcg/kg)
Trial: NCT05597280
Drug: BE-PEP Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bedaquiline
Trial: NCT05597280
Drug: SDR-PEP Rifampicin
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDR-PEP: rifampicin
Trial: NCT05597280
Drug: BE-PEP Rifampicin
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BE-PEP rifampicin
Trial: NCT06169735
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
Trial: NCT06186622
Drug: Orforglipron
RxNorm normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05669170
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norepinephrine and dopamine reuptake inhibitor
Trial: NCT05589441
Drug: salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
Trial: NCT05589441
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
Trial: NCT06186622
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06186622
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT06186622
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00269958
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05728008
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
Trial: NCT05728008
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
Trial: NCT01218698
Drug: Losartan Potassium Tablets
RxNorm normalized name: Losartan Potassium Tablets
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05531708
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
Trial: NCT05079126
Drug: Trans Sodium Crocetinate
RxNorm normalized name: trans-crocetin
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV Bolus
Trial: NCT05141149
Drug: PBP1510 (400mg/16mL)
RxNorm normalized name: Immunoglobulin g1, anti-(human pancreatic adenocarcinoma up-regulated factor) (human-mus musculus monoclonal pbp1510 .gamma.1-chain), disulfide with human-mus musculus monoclonal pbp1510 .kappa.-chain, dimer
DrugBank: Ulenistamab (DB18291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
Trial: NCT05141149
Drug: Gemcitabine (1000 mg/m^2)
RxNorm normalized name: gemcitabine 1000 MG
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
Trial: NCT04771390
Drug: Selitrectinib (BAY2731954) Adult tablet
RxNorm normalized name: entrectinib
DrugBank: Selitrectinib (DB14896)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, oral administration
Trial: NCT04771390
Drug: Selitrectinib (BAY2731954) Pediatric tablet
RxNorm normalized name: Selitrectinib
DrugBank: Selitrectinib (DB14896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT04771390
Drug: Selitrectinib (BAY2731954) Oral solution
RxNorm normalized name: entrectinib Oral Product
DrugBank: Selitrectinib (DB14896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution after reconstitution
Trial: NCT04771390
Drug: Selitrectinib (BAY2731954) Oral suspension
RxNorm normalized name: entrectinib Oral Product
DrugBank: Selitrectinib (DB14896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension after reconstitution
Trial: NCT04971447
Drug: gender affirming hormonal treatment in transgender men
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: testosterone enanthate
Trial: NCT05320081
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
Trial: NCT04971447
Drug: gender affirming hormonal treatment in transgender women
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists + estrogen
Trial: NCT05861063
Drug: Dezocine
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
Trial: NCT06436144
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
Trial: NCT05544214
Drug: CKD-371
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT06186895
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
Trial: NCT04614194
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral. Tablets should be taken at the same times every day, with or without food.
Trial: NCT04614194
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral. Tablets should be taken at the same times every day, with or without food.
Trial: NCT05372588
Drug: NVX-CoV2515
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
Trial: NCT05372588
Drug: NVX-Cov2373
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
Trial: NCT05372588
Drug: NVX-CoV2373 + NVX-CoV2515
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
Trial: NCT05372588
Drug: NVX-CoV2540
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
Trial: NCT05372588
Drug: NVX-CoV2373 + NVX-CoV2540
RxNorm normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
Trial: NCT04857606
Drug: AMG 609
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AMG 609 administered as a subcutaneous injection.
Trial: NCT06141889
Drug: Azelaprag
RxNorm normalized name: Azelaprag
DrugBank: Azelaprag (DB19329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, apelin receptor (APJ) agonist
Trial: NCT05951309
Drug: Glucophage 500Mg Tablet
RxNorm normalized name: Glucophage 500mg Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients in this group were given glucophage three times a day for 12-16 weeks
Trial: NCT06516861
Drug: Magnesium Sulfate 20 MG/ML
RxNorm normalized name: magnesium sulfate 20 MG/ML
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously with a dose of 30 mg/kg
Trial: NCT06516861
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously with a dose of 1.5mg/Kg
Trial: NCT06516861
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously with 20 ml
Trial: NCT05624112
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab solution in a pre-filled syringe for Subcutaneous injection
Trial: NCT04728724
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines.